Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo – a post-hoc analysis of the BACE randomized controlled trial

Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo – a post-hoc analysis of the BACE randomized controlled trial

Abstract Background In the BACE trial, a 3-month (3 m) intervention with azithromycin, initiated at the onset of an infectious COPD exacerbation requiring hospitalization, decreased the rate of a first treatment failure (TF); the composite of treatment intensification (TI), step-up in hospital care...

Full description

Bibliographic Details
Main Authors: Kristina Vermeersch, Ann Belmans, Kris Bogaerts, Iwein Gyselinck, Nina Cardinaels, Maria Gabrovska, Joseph Aumann, Ingel K. Demedts, Jean-Louis Corhay, Eric Marchand, Hans Slabbynck, Christel Haenebalcke, Stefanie Vermeersch, Geert M. Verleden, Thierry Troosters, Vincent Ninane, Guy G. Brusselle, Wim Janssens, On behalf of the BACE trial investigators
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Respiratory Research
Subjects:
Recurrent event
Readmission
Macrolide
CRP
Eosinophil count
Online Access:http://link.springer.com/article/10.1186/s12931-019-1208-6

Internet

http://link.springer.com/article/10.1186/s12931-019-1208-6

Similar Items